Hedge Fund - VenBio Select Advisor
Ascendis Pharma A/S (ASND)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2025 - Q1 (2025-03-31) | $813,277,480 | 12.69% | 5,218,000 | $142.85 |
| 2 | 2024 - Q4 (2024-12-31) | $702,537,582 | 9.93% | 5,103,055 | $131.48 |
| 3 | 2024 - Q3 (2024-09-30) | $744,890,867 | 10.86% | 4,988,888 | $135.05 |
| 4 | 2024 - Q2 (2024-06-30) | $572,340,627 | 7.62% | 4,196,661 | $136.06 |
| 5 | 2024 - Q1 (2024-03-31) | $599,640,899 | 6.99% | 3,966,666 | $142.72 |
| 6 | 2023 - Q4 (2023-12-31) | $473,012,152 | 6.53% | 3,755,555 | $99.70 |
| 7 | 2023 - Q3 (2023-09-30) | $343,658,800 | 5.36% | 3,670,000 | $93.55 |
| 8 | 2023 - Q2 (2023-06-30) | $319,564,534 | 4.33% | 3,580,555 | $87.09 |
| 9 | 2023 - Q1 (2023-03-31) | $356,506,500 | 5.28% | 3,325,000 | $114.40 |
| 10 | 2022 - Q4 (2022-12-31) | $378,603,000 | 5.65% | 3,100,000 | $116.10 |
| 11 | 2022 - Q3 (2022-09-30) | $294,291,000 | 5.43% | 2,850,000 | $94.81 |
| 12 | 2022 - Q2 (2022-06-30) | $211,484,000 | 4.17% | 2,275,000 | $94.25 |
| 13 | 2022 - Q1 (2022-03-31) | $258,192,000 | 4.71% | 2,200,000 | $115.81 |
| 14 | 2021 - Q4 (2021-12-31) | $269,060,000 | 4.57% | 2,000,000 | $148.75 |
| 15 | 2021 - Q3 (2021-09-30) | $315,592,000 | 4.95% | 1,980,000 | $136.86 |
| 16 | 2021 - Q2 (2021-06-30) | $249,945,000 | 4.34% | 1,900,000 | $133.25 |
| 17 | 2021 - Q1 (2021-03-31) | $0 | 0% | 0 | $151.98 |
| 18 | 2020 - Q4 (2020-12-31) | $300,204,000 | 5.17% | 1,800,000 | $165.37 |
| 19 | 2020 - Q3 (2020-09-30) | $277,776,000 | 3.94% | 1,800,000 | $143.74 |
| 20 | 2020 - Q2 (2020-06-30) | $258,825,000 | 5.11% | 1,750,000 | $137.30 |
| 21 | 2020 - Q1 (2020-03-31) | $201,234,000 | 6.79% | 1,787,000 | $129.93 |
| 22 | 2019 - Q4 (2019-12-31) | $259,459,000 | 7.61% | 1,865,000 | $111.10 |
| 23 | 2019 - Q3 (2019-09-30) | $189,750,000 | 7.91% | 1,970,000 | $111.55 |
| 24 | 2019 - Q2 (2019-06-30) | $226,846,000 | 7.84% | 1,970,000 | $119.66 |
| 25 | 2019 - Q1 (2019-03-31) | $211,272,000 | 9.13% | 1,795,000 | $87.57 |
| 26 | 2018 - Q4 (2018-12-31) | $124,047,000 | 7.41% | 1,980,000 | $62.83 |
| 27 | 2018 - Q3 (2018-09-30) | $139,122,000 | 6.38% | 1,963,336 | $68.83 |
| 28 | 2018 - Q2 (2018-06-30) | $137,253,000 | 5.28% | 2,063,336 | $65.76 |
| 29 | 2018 - Q1 (2018-03-31) | $134,942,000 | 6.44% | 2,063,336 | $56.20 |
| 30 | 2017 - Q4 (2017-12-31) | $67,342,000 | 4.36% | 1,681,024 | $36.36 |
| 31 | 2017 - Q3 (2017-09-30) | $59,309,000 | 4.6% | 1,636,124 | $28.70 |
| 32 | 2017 - Q2 (2017-06-30) | $27,508,000 | 3.47% | 990,924 | $26.42 |
| 33 | 2017 - Q1 (2017-03-31) | $19,626,000 | 2.5% | 700,924 | $25.27 |
| 34 | 2016 - Q4 (2016-12-31) | $11,035,000 | 2.22% | 545,203 | $19.97 |
| 35 | 2016 - Q3 (2016-09-30) | $909,000 | 0.15% | 45,203 | $16.51 |
The displayed share prices are average quarterly stock market prices.